Corrigenda: A practice tool for the new oral anticoagulants [Can Pharm J (Ott), 147, (2014) 25-32, DOI 10.1177/1715163513513869];A practice tool for the new oral anticoagulants

Canadian Pharmacists Journal

Volumn 147, Issue 1, 2014, Pages 25-32

  Massicotte, Anne ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; PRODRUG; RIVAROXABAN; WARFARIN;

ARTICLE; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SUBSTITUTION; HUMAN; KIDNEY FUNCTION; LUNG EMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84893507765     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163514550673     Document Type: Erratum

References (20)

1. Burlington:; 2013:.
2. Toronto (ON):; 2013:.
3. Kirkland (ON):; 2012:.
4. Schulman S,Crowther MA.How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.Blood. 2012;119:3016-23.
5. Levy JH,Key NS,Azran MS.Novel oral anticoagulants: implications in the perioperative setting.Anesthesiology. 2010;113:726-45.
6. Trujillo TC.Emerging anticoagulants for venous thromboembolism prevention.Am J Health Syst Pharm. 2010;67:S17-25.
7. Dabigatran etexilate. In: DRUGDEX System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available: http://www.micromedexsolutions.com (accessed Aug. 7, 2013).
8. Rivaroxaban, In: DRUGDEX System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available: http://www.micromedexsolutions.com (accessed Aug. 7, 2013).
9. Douketis JD.Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.Curr Pharm Design. 2010;16:3436-41.
10. Lexi-Drugs. Available: http://online.lexi.com/lco/action/home/switch (accessed Aug. 7, 2013).
11. Lexi-Interact. Available: http://online.lexi.com/lco/action/interact (accessed Aug. 7, 2013).
12. Horn JR,Hansten PD.Drug interactions with digoxin: the role of P-glycoprotein.Pharmacy Times. 2004;45:114.
13. Spyropoulos AC,Douketis JD.How I treat anticoagulated patients undergoing an elective procedure or surgery.Blood. 2012;120:2954-62.
14. Barrett YC,Wang Z,Frost C,Shenker A.Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.Thromb Haemost. 2010;104:1263-71.
15. Samama MM,Guinet C.Laboratory assessment of new anticoagulants.Clin Chem Lab Med. 2011;49:761-72.
16. Miyares MA,Davis K.Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.Am J Health Syst Pharm. 2012;69:1473-84.
17. Bauer KA.Reversal of antithrombotic agents.Am J Hematol. 2012;87:S119-26.
18. Kaatz S,Kouides PA,Garcia DA, et al.Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.Am J Hematol. 2012;87:S141-5.
19. van RynJSiegerPKink-EibandM. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. In: 51st ASH Annual Meeting and Exposition, New Orleans (LA): American Society of Hematology; 2009. Available: http://ash.confex.com/ash/2009/webprogram/Paper21383.html (accessed Aug. 7, 2013).
20. Stangier J,Rathgen K,Stahle H,Mazur D.Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate.Clin Pharmacokinet. 2010;49:259-68.